Abbott Laboratories (ABT) Total Current Liabilities (2009 - 2026)

Abbott Laboratories has disclosed Total Current Liabilities across 18 years of filings, most recently posting $18.4 billion for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $18.4 billion, up 41.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.4 billion (up 41.32% YoY), and the FY2025 annual result was $16.5 billion, up 16.52% from the prior year.
• Total Current Liabilities came in at $18.4 billion for Q1 2026 at Abbott Laboratories, up from $16.5 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $18.4 billion in Q1 2026 to a low of $12.4 billion in Q2 2022.
• The 5-year median for Total Current Liabilities is $14.0 billion (2024), against an average of $14.3 billion.
• Across the five-year window, Total Current Liabilities fell 10.64% in 2023 and jumped 41.32% in 2026, its largest moves.
• Abbott Laboratories' Total Current Liabilities stood at $15.5 billion in 2022, then retreated by 10.64% to $13.8 billion in 2023, then increased by 2.28% to $14.2 billion in 2024, then climbed by 16.52% to $16.5 billion in 2025, then advanced by 11.4% to $18.4 billion in 2026.
• The last three Total Current Liabilities figures came in at $18.4 billion (Q1 2026), $16.5 billion (Q4 2025), and $14.6 billion (Q3 2025), per Business Quant data.